| Literature DB >> 27447599 |
Toshio Morikawa1,2, Niichiro Kitagawa3,4, Genzoh Tanabe5, Kiyofumi Ninomiya6,7, Shuhei Okugawa8,9, Chiaki Motai10,11, Iyori Kamei12, Masayuki Yoshikawa13, I-Jung Lee14, Osamu Muraoka15,16,17.
Abstract
A quantitative analytical method for five aporphine alkaloids,Entities:
Keywords: Nelumbo nucifera; carbamate salt; lotus flower; melanogenesis inhibitor; nornuciferine; nuciferine; quantitative analysis
Mesh:
Substances:
Year: 2016 PMID: 27447599 PMCID: PMC6272935 DOI: 10.3390/molecules21070930
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Inhibitory effects of the methanol extract and its fractions from lotus flower on theophylline-stimulated melanogenesis and viability in B16 4A5 cells.
| Treatment a | Inhibition (%) | IC50
| ||||
|---|---|---|---|---|---|---|
| 0 µg/mL | 3 µg/mL | 10 µg/mL | 30 µg/mL | 100 µg/mL | ||
| MeOH ext. | 0.0 ± 1.3 | 28.3 ± 3.7 | 68.9 ± 3.1 ** | 96.4 ± 3.1 ** | 97.0 ± 3.3 ** | 5.6 |
| EtOAc-soluble fraction | 0.0 ± 6.1 | 11.0 ± 1.7 | 51.5 ± 5.3 ** | 83.0 ± 2.9 ** | 100.9 ± 3.4 ** | 11.1 |
| 0.0 ± 13.3 | 17.6 ± 7.0 | 35.9 ± 7.1 | 72.3 ± 4.7 ** | 94.7 ± 3.5 ** | 13.7 | |
|
| ||||||
| CHCl3-soluble fraction | 0.0 ± 1.7 | 19.8 ± 6.8 | 35.6 ± 6.6 ** | 79.2 ± 2.3 ** | 107.2 ± 3.0 ** | 0.37 |
Each value represents the mean ± S.E.M. (n = 4); asterisks denote significant differences from the control group, ** p < 0.01; a Bioassay-guided separation study was carried out using the flower buds of N. nucifera originating in Thailand (NN-1).
Figure 1Aporphine and benzylisoquinoline alkaloids (1–10) from lotus flower.
Figure 2A typical LC-MS chromatogram of a standard solution mixture (each 10 µg/mL) of alkaloids (1–10). (a) SIM chromatogram (positive ESI); (b) HPLC chromatogram (UV: 260 nm).
Extraction efficiently of alkaloids (1–10) from lotus flower.
| Extraction Method | Extraction Yield (%) | Contents (mg/g in Dry Material) a | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |||
| Methanol, reflux | 15.0 | 1.76 (100) | 1.75 (100) | 0.07 (100) | 0.63 (100) | 0.69 (100) | 0.83 (100) | 1.45 (100) | 5.73 (100) | 1.30 (100) | 0.75 (100) | 14.96 (100) |
| 50% Methanol, reflux | 25.3 | 1.09 (62) | 1.35 (77) | 0.05 (71) | 0.50 (79) | 0.61 (88) | 0.78 (94) | 1.35 (93) | 3.79 (66) | 0.94 (73) | 0.56 (75) | 11.02 (74) |
| H2O, reflux | 23.1 | 0.24 (14) | 0.35 (20) | n.d. b | 0.21 (33) | 0.18 (26) | 0.38 (45) | 0.78 (54) | 2.57 (45) | 0.66 (51) | 0.29 (38) | 5.66 (38) |
| Methanol, sonication | 9.6 | 0.88 (50) | 1.11 (64) | 0.03 (44) | 0.39 (62) | 0.33 (48) | 0.47 (56) | 0.97 (67) | 2.77 (48) | 0.70 (54) | 0.42 (56) | 8.07 (54) |
| 50% Methanol, sonication | 22.0 | 0.98 (56) | 1.27 (73) | 0.04 (58) | 0.49 (78) | 0.47 (69) | 0.80 (96) | 1.38 (95) | 3.93 (69) | 0.97 (75) | 0.59 (79) | 10.92 (73) |
| H2O, sonication | 19.3 | 0.14 (8) | 0.21 (12) | n.d. b | 0.12 (20) | 0.08 (11) | 0.25 (30) | 0.53 (37) | 1.91 (33) | 0.48 (37) | 0.19 (26) | 3.91 (26) |
Extraction efficiently was tested using NN-1 (loss of drying 10.33%); a relative value (%) against the content obtained by methanol under reflux is given in parentheses; b less than the quantitation limit.
Linearities, detection and quantitation limits, and precisions for alkaloids (1–10) in lotus flower.
| Analyte | Regression Equation a | Correlation Coefficient | Detection Limit b (ng) | Quantitation Limit b (ng) | Precision c (RSD, %) | |
|---|---|---|---|---|---|---|
| Intra-Day | Inter-Day | |||||
| Nuciferine ( | 0.9998 | 0.17 | 0.51 | 0.25 | 0.59 | |
| Nornuciferine ( | 1.0000 | 0.71 | 2.16 | 0.79 | 0.43 | |
| 0.9996 | 0.32 | 0.99 | 1.36 | 1.40 | ||
| Asimilobine ( | 0.9999 | 0.70 | 2.13 | 0.63 | 0.57 | |
| Pronuciferine ( | 0.9998 | 0.73 | 2.18 | 0.95 | 1.08 | |
| Armepavine ( | 0.9999 | 0.32 | 0.97 | 0.68 | 1.10 | |
| Norarmepavine ( | 0.9999 | 0.81 | 2.47 | 0.54 | 0.73 | |
| 0.9999 | 0.90 | 2.71 | 0.59 | 0.86 | ||
| Coclaurine ( | 0.9999 | 0.44 | 1.33 | 0.98 | 0.39 | |
| Norjuziphine ( | 1.0000 | 0.88 | 2.65 | 0.64 | 0.66 | |
a In the regression equation, x is the concentration of the analyte solution (µg/mL), and y is the peak area of the analyte; b values are the amount of the analyte injected on-column and c precision of the analytical method were tested using the methanol extract of NN-1 (n = 5).
Recoveries for alkaloids (1–10) from lotus flower.
| Add (µg/mL) | Recovery a (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| 10 | 98.7 ± 0.6 | 101.4 ± 0.7 | 95.3 ± 1.0 | 99.0 ± 0.9 | 93.2 ± 0.7 | 98.5 ± 0.3 | 104.0 ± 0.7 | 94.7 ± 1.4 | 97.4 ± 0.2 | 97.4 ± 1.0 |
| 15 | 92.3 ± 0.4 | 101.7 ± 0.2 | 97.5 ± 0.7 | 101.8 ± 0.1 | 98.1 ± 0.5 | 102.2 ± 0.6 | 99.4 ± 1.1 | 99.8 ± 1.6 | 104.0 ± 0.2 | 100.2 ± 0.8 |
| 20 | 98.4 ± 0.1 | 105.8 ± 0.7 | 101.2 ± 0.8 | 102.0 ± 0.7 | 95.9 ± 0.8 | 105.1 ± 0.6 | 99.9 ± 0.9 | 96.3 ± 1.1 | 105.8 ± 0.3 | 95.3 ± 0.8 |
a The recovery rates were determined by adding analytes of three different concentrations (10, 15, and 20 µg/mL) to the sample solution; recoveries spiked with the methanol extract of NN-1 (each 400 µg/mL, n = 3).
Contents of alkaloids (1–10) in the methanol extracts from lotus flower.
| Sample No. | Part | Loss of Drying a (%) | Extraction Yield b (%) | Contents (mg/g in Dry Material) a | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |||||
| NN-1 | whole flowers | 10.3 | 15.0 | 1.76 | 1.75 | 0.07 | 0.63 | 0.69 | 0.83 | 1.45 | 5.73 | 1.30 | 0.75 | 14.96 |
| NN-2 | petals | 8.6 | 16.6 | 1.99 | 2.41 | 0.07 | 1.22 | 0.62 | 1.02 | 1.74 | 5.85 | 1.60 | 0.52 | 17.04 |
| NN-3 | receptacles | 10.0 | 8.6 | 0.06 | 0.07 | n.d. c | 0.01 | 0.01 | 0.01 | 0.01 | 0.20 | 0.04 | n.d. c | 0.41 |
| NN-4 | stamens | 8.6 | 20.0 | 0.58 | 0.68 | n.d. c | 0.25 | 0.23 | 0.47 | 0.64 | 2.88 | 0.60 | 0.32 | 6.65 |
| NN-5 | whole flowers | 8.1 | 16.3 | 0.56 | 0.27 | n.d. c | 0.04 | n.d. c | 0.23 | 0.34 | 1.74 | 0.19 | 0.16 | 3.53 |
| NN-6 | petals | 7.3 | 19.0 | 0.80 | 0.34 | n.d. c | n.d. c | 0.01 | 0.36 | 0.52 | 3.14 | 0.32 | 0.27 | 5.76 |
| NN-7 | receptacles | 9.2 | 7.4 | 0.27 | 0.53 | n.d. c | n.d. c | 0.05 | 0.03 | 0.03 | 0.74 | 0.27 | n.d.c | 1.92 |
| NN-8 | stamens | 7.9 | 15.5 | 0.01 | n.d. c | n.d. c | n.d. c | n.d. c | n.d. c | n.d. c | 0.03 | 0.01 | 0.03 | 0.08 |
a Each powdered sample was dried at 105 °C for 8 h; b each powdered sample was extracted two times with methanol under reflux for 120 min and c less than the quantitation limit.
Figure 3Chemical transformation of nornuciferine (2) into its ammonium carbamate salt (2′′) and to methyl carbamate (2a).
1H- (800 MHz) and 13C- (200 MHz) NMR data for 2′′, 2a, and original alkaloid 2 in CDCl3.
| Position | 2′′ (anion part) | Position | 2′′ (cation part) | ||
|---|---|---|---|---|---|
| δH ( | δC | δH ( | δC | ||
| 1 | 146.0 a | 1′ | 146.2 a | ||
| 2 | 152.5 b | 2′ | 153.7 b | ||
| 3 | 6.69 (s) | 111.4 | 3′ | 6.67 (s) | 111.4 |
| 3a | 128.7 | 3a′ | 125.7 | ||
| 4 | 2.74 (br d, ca. 15)
| 29.9, 30.2 | 4′ | 2.95 (dd, 3.8, 16.8)
| 25.5 |
| 5 | 3.20–3.35 (m)
| 41.8, 44.4 | 5′ | 3.24 (br ddd-like, ca. 13.5, 13.5, 13.5)
| 41.4 |
| 6a | 4.92 (br d, ca. 13) | 54.9, 55.8 | 6a′ | 4.29 (br dd-like, ca. 13.5, 13.5) | 53.0 |
| 7 | 2.86–2.90 (m)
| 33.9, 35.9 | 7′ | 3.38 (dd, 13.5, 13.5)
| 34.0 |
| 7a | 135.7 | 7a′ | 133.1 | ||
| 8 | 7.24–7.30 (m) | 128.0 c | 8′ | 7.24–7.30 (m) | 128.3 c |
| 9 | 7.24–7.30 (m) | 127.4 c | 9′ | 7.24–7.30 (m) | 128.2 c |
| 10 | 7.35 (m) | 127.3 c | 10′ | 7.35 (m) | 127.8 c |
| 11 | 8.44 (br s-like) | 128.5 c | 11′ | 8.41 (d, 7.9) | 128.6 c |
| 11a | 131.3 | 11a′ | 131.3 | ||
| 11b | 127.5 d | 11b′ | 127.0 d | ||
| 11c | 124.8, 124.9 | 11c′ | 121.4 | ||
| 1-O | 3.667 e (s) | 60.3 f | 1′-O | 3.673 e (s) | 60.0 f |
| 2-O | 3.90 g (s) | 56.0 h | 2′-O | 3.91 g (s) | 55.9 h |
| 157.5, 160.1 | 9.96 (br ddd-like, ca. 13.5, 13.5, 13.5 )
| ||||
|
|
|
|
| ||
|
|
|
|
| ||
| 1 | 145.7 | 1 | 145.3 | ||
| 2 | 152.1 | 2 | 152.2 | ||
| 3 | 6.67 (s) | 111.5 | 3 | 6.65 (s) | 111.8 |
| 3a | 126.1 | 3a | 128.5 | ||
| 4 | 2.65 (br d, ca. 15)
| 30.3 | 4 | 2.71 (d, 13.1)
| 28.9 |
| 5 | 3.00 (br dd, ca. 11, 13)
| 38.8 | 5 | 3.01 (m)
| 43.0 |
| 6a | 4.46 (br s) | 51.4 | 6a | 3.85 (br dd, ca. 5, 14) | 53.5 |
| 7 | 2.86 (m)
| 35.2 | 7 | 2.77 (t, 13.8)
| 37.3 |
| 7a | 136.8 | 7a | 135.9 | ||
| 8 | 7.25 (dd, 1.6, 7.8) | 128.2 | 8 | 7.24 (m) | 127.8 |
| 9 | 7.27 (br dd, ca. 8, 8) | 127.5 | 9 | 7.21 (ddd, 1.1, 7.1, 7.1) | 127.4 |
| 10 | 7.32 (ddd, 1.6, 7.8, 8.0) | 126.9 | 10 | 7.30 (m) | 127.0 |
| 11 | 8.44 (br d, ca. 8) | 128.3 | 11 | 8.39 (br d, ca. 8) | 128.4 |
| 11a | 131.7 | 11a | 132.1 | ||
| 11b | 127.6 | 11b | 126.5 | ||
| 11c | 129.7 | 11c | 128.7 | ||
| 1-O | 3.66 (s) | 60.2 | 1-O | 3.67 (s) | 60.2 |
| 2-O | 3.90 (s) | 56.0 | 2-O | 3.88 (s) | 55.9 |
| 156.0 | |||||
| 3.76 (s) | 52.6 | ||||
a–h May be interchangeable.
Figure 4The reported reactivity of amines with CO2.
Inhibitory effects of the alkaloids (1–10) and 2a on theophylline-stimulated melanogenesis and viability in B16 4A5 cells.
| Treatment | Inhibition (%) | IC50 | |||||
|---|---|---|---|---|---|---|---|
| 0 µM | 3 µM | 10 µM | 30 µM | 100 µM | (µM) | (µg/mL) b | |
| Nuciferine·HCl ( | 0.0 ± 4.0
| 28.3 ± 4.2 **
| 57.8 ± 2.3 **
| 89.7 ± 1.7 **
| 91.8 ± 2.6 **
| 7.1 | 2.4 |
| Nornuciferine·HCl ( | 0.0 ± 3.4
| 44.6 ± 3.4 **
| 70.6 ± 3.6 **
| 94.3 ± 3.2 **
| — | 3.9 | 1.2 |
| 0.0 ± 4.7
| 3.3 ± 2.9
| 19.5 ± 2.4 **
| 63.4 ± 5.2 **
| 89.8 ± 2.1 **
| 43.1 | 13.7 | |
| Asimilobine·HCl ( | 0.0 ± 8.1
| 16.2 ± 12.8
| 31.9 ± 2.2 **
| 87.2 ± 3.3 **
| — | 11.3 | 3.4 |
| Pronuciferine·HCl ( | 0.0 ± 10.7
| 23.1 ± 3.4
| 18.8 ± 1.2
| 37.2 ± 2.6 **
| 88.4 ± 3.7 **
| 47.1 | 16.3 |
| Armepavine·HCl ( | 0.0 ± 6.0
| 33.9 ± 0.8 **
| 58.5 ± 7.1 **
| 81.8 ± 3.0 **
| 97.4 ± 0.4 **
| 6.5 | 3.4 |
| Norarmepavine·HCl ( | 0.0 ± 3.1
| 32.6 ± 4.4 **
| 53.5 ± 8.5 **
| 81.6 ± 1.4 **
| 90.5 ± 1.2 **
| 7.5 | 2.5 |
| 0.0 ± 5.4
| 38.6 ± 2.4 **
| 55.7 ± 3.4 **
| 74.7 ± 2.0 **
| —
| 6.5 | 2.2 | |
| Coclaurine·HCl ( | 0.0 ± 2.9
| 45.6 ± 7.7 **
| 65.4 ± 2.5 **
| 82.4 ± 3.5 **
| 68.0 ± 6.4 **
| 3.9 | 1.3 |
| Norjuziphine·HCl ( | 0.0 ± 5.4
| 18.5 ± 4.0 *
| 36.8 ± 4.5 **
| 94.4 ± 2.0 **
| 106.0 ± 2.0 **
| 14.4 | 4.6 |
|
| 0.0 ± 7.3
| 13.1 ± 8.9
| 43.1 ± 7.8 **
| 54.5 ± 4.3 **
| — | 19.9 | 6.7 |
| Arbutin [ | 0.0 ± 1.4
| 20.4 ± 0.5
| 38.1 ± 0.9 **
| 61.5 ± 0.6 **
| 83.7 ± 0.5 **
| 174 | 47.4 |
Each value represents the mean ± S.E.M. (n = 4); asterisks denote significant differences from the control group, * p < 0.05, ** p < 0.01; # cytotoxic effects were observed, and values in parentheses indicate cell viability (%) in MTT assay; commercial arubutin was purchased from Nakalai Tesque Inc., (Kyoto, Japan); a each alkaloid was evaluated by its hydrochloride salt; b each IC50 value was converted to µg/mL of corresponding free alkaloid.
Effects on activity of tyrosinase from mushroom.
| Substrate:Treatment | Inhibition (%) | |||||
|---|---|---|---|---|---|---|
| 0 µM | 10 µM | 100 µM | 0 µM | 10 µM | 100 µM | |
| Nuciferine·HCl ( | 0.0 ± 3.2 | 6.5 ± 3.3 | 30.4 ± 1.9 ** | 0.0 ± 2.9 | 4.4 ± 3.8 | 11.0 ± 3.4 |
| Nornuciferine·HCl ( | 0.0 ± 2.6 | 1.0 ± 0.7 | 14.2 ± 1.5 ** | 0.0 ± 3.1 | 15.4 ± 4.1 | 8.7 ± 4.1 |
| 0.0 ± 3.6 | 7.2 ± 7.3 | 0.8 ± 3.5 | 0.0 ± 1.5 | 2.3 ± 1.5 | 3.1 ± 3.9 | |
| Asimilobine·HCl ( | 0.0 ± 1.8 | 10.5 ± 2.5 * | 14.0 ± 1.2 ** | 0.0 ± 3.3 | 3.2 ± 2.4 | 5.7 ± 3.0 |
| Pronuciferine·HCl ( | 0.0 ± 5.3 | −0.4 ± 2.4 | −4.4 ± 8.1 | 0.0 ± 2.0 | 6.5 ± 2.0 | 5.3 ± 5.2 |
| Armepavine·HCl ( | 0.0 ± 4.4 | −1.9 ± 0.9 | 40.2 ± 3.7 ** | 0.0 ± 0.5 | 4.5 ± 0.8 | 2.9 ± 1.2 |
| Norarmepavine·HCl ( | 0.0 ± 1.8 | −1.7 ± 1.5 | 23.3 ± 1.6 ** | 0.0 ± 2.7 | −1.3 ± 1.4 | 1.5 ± 1.5 |
| 0.0 ± 5.2 | −5.0 ± 5.7 | 15.3 ± 4.3 | 0.0 ± 2.3 | 6.1 ± 1.4 | 7.4 ± 0.8 | |
| Coclaurine·HCl ( | 0.0 ± 2.3 | 9.0 ± 0.7 * | 35.1 ± 1.7 ** | 0.0 ± 2.5 | −4.9 ± 1.1 | 4.4 ± 1.1 |
| Norjuziphine·HCl ( | 0.0 ± 2.5 | 5.1 ± 1.1 | 27.4 ± 3.0 ** | 0.0 ± 2.0 | 1.8 ± 0.7 | 22.3 ± 3.6 ** |
| 0.0 ± 1.5 | 5.3 ± 1.7 | 2.9 ± 0.7 | 0.0 ± 2.7 | 3.2 ± 1.1 | 6.6 ± 2.3 | |
| Kojic acid [ | 0.0 ± 2.4 | 12.2 ± 3.3 | 46.4 ± 2.6 ** | 66.5 ± 2.1 ** | 96.8 ± 0.9 ** | 43.6 |
| Kojic acid [ | 0.0 ± 0.9 | 22.3 ± 2.1 ** | 50.6 ± 0.6 ** | 78.2 ± 0.7 ** | 89.3 ± 0.3 ** | 29.6 |
Each value represents the mean ± S.E.M. (n = 4); asterisks denote significant differences from the control group, * p < 0.05, ** p < 0.01; commercial kojic acid was purchased from Nakalai Tesque Inc., (Kyoto, Japan); a each alkaloid was evaluated by its hydrochloride salt.
Effects of 1, 2, 6, 7, and 9 on expression of tyrosinase, TRP-1, and TRP-2 mRNA in B16 4A5 cells.
| Treatment | Tyrosinase mRNA/-actin mRNA | ||
|---|---|---|---|
| 0 µM | 3 µM | 10 µM | |
| Nuciferine·HCl ( | 1.00 ± 0.15 | 0.59 ± 0.03 * | 0.45 ± 0.05 * |
| Nornuciferine·HCl ( | 1.00 ± 0.19 | 0.76 ± 0.05 | 0.51 ± 0.10 |
| Armepavine·HCl ( | 1.00 ± 0.14 | 0.86 ± 0.13 | 0.74 ± 0.02 |
| Norarmepavine·HCl ( | 1.00 ± 0.24 | 0.81 ± 0.08 | 1.00 ± 0.11 |
| Coclaurine·HCl ( | 1.00 ± 0.14 | 0.82 ± 0.21 | 0.52 ± 0.05 |
| Nuciferine·HCl ( | 1.00 ± 0.12 | 1.18 ± 0.17 | 1.18 ± 0.25 |
| Nornuciferine·HCl ( | 1.00 ± 0.10 | 1.21 ± 0.18 | 1.15 ± 0.19 |
| Armepavine·HCl ( | 1.00 ± 0.22 | 0.98 ± 0.32 | 0.83 ± 0.15 |
| Norarmepavine·HCl ( | 1.00 ± 0.09 | 0.87 ± 0.22 | 1.03 ± 0.25 |
| Coclaurine·HCl ( | 1.00 ± 0.24 | 0.51 ± 0.08 | 0.66 ± 0.13 |
| Nuciferine·HCl ( | 1.00 ± 0.16 | 1.33 ± 0.35 | 0.87 ± 0.16 |
| Nornuciferine·HCl ( | 1.00 ± 0.12 | 0.92 ± 0.20 | 1.36 ± 0.09 |
| Armepavine·HCl ( | 1.00 ± 0.05 | 1.07 ± 0.22 | 0.81 ± 0.22 |
| Norarmepavine·HCl ( | 1.00 ± 0.18 | 0.80 ± 0.24 | 0.77 ± 0.14 |
| Coclaurine·HCl ( | 1.00 ± 0.11 | 1.02 ± 0.22 | 1.07 ± 0.07 |
Each value represents the mean ± S.E.M. (n = 3); asterisks denote significant differences from the control group, * p < 0.05; a each alkaloid was evaluated by its hydrochloride salt.
Inhibitory effects of the methanol extract from lotus flower (NN-1–NN-8) on theophylline-stimulated melanogenesis and viability in B16 4A5 cells.
| Sample No. | Inhibition (%) | IC50 | ||||
|---|---|---|---|---|---|---|
| 0 µg/mL | 3 µg/mL | 10 µg/mL | 30 µg/mL | 100 µg/mL | (µg/mL) | |
| NN-1 | 0.0 ± 1.3 | 28.3 ± 3.7 | 68.9 ± 3.1 ** | 96.4 ± 3.1 ** | 97.0 ± 3.3 ** | 5.6 |
| NN-2 | 0.0 ± 5.7 | 15.7 ± 8.2 | 49.9 ± 12.0 ** | 108.2 ± 4.1 ** | 103.8 ± 6.7 ** | 8.8 |
| NN-3 | 0.0 ± 5.9 | 18.6 ± 4.2 | 26.1 ± 5.0 ** | 72.9 ± 0.7 ** | 86.8 ± 4.1 ** | 34.7 |
| NN-4 | 0.0 ± 10.0 | 10.7 ± 8.1 | 28.3 ± 4.7 | 95.7 ± 1.6 ** | 107.0 ± 2.1 ** | 24.0 |
| NN-5 | 0.0 ± 7.3 | 23.7 ± 4.0 ** | 34.4 ± 5.1 ** | 86.6 ± 2.6 ** | 103.4 ± 1.9 ** | 19.9 |
| NN-6 | 0.0 ± 6.0 | −6.9 ± 13.7 | −6.3 ± 12.0 | 77.4 ± 5.4 ** | 104.6 ± 2.1 ** | 54.1 |
| NN-7 | 0.0 ± 4.4 | −9.5 ± 6.9 | 9.0 ± 7.6 | 79.4 ± 2.1 ** | 84.2 ± 4.2 ** | 46.6 |
| NN-8 | 0.0 ± 1.7 | −3.3 ± 4.8 | 1.3 ± 7.9 | 57.6 ± 3.1 ** | 64.9 ± 2.3 ** | 78.9 |
Each value represents the mean ± S.E.M. (n = 4); asterisks denote significant differences from the control group, ** p < 0.01.; # cytotoxic effects were observed, and values in parentheses indicate cell viability (%) in MTT assay.
Figure 5Correlations between the melanogenesis inhibitory activities and total content. (a) Total content (%) of 10 alkaloids (1–10); (b) Total content (%) of two principal alkaloids (1 and 2). Total contents (%) of the alkaloids are presented in values reduced to the content of nuciferine (1), calculated based on the ratio of IC50 values (µg/mL) against melanogenesis inhibitory activities.